Rediscovering and harnessing breakthroughs in medical science to develop effective, affordable treatments for chronic health conditions.
MedResearch began in Australia with a singular focus: to explore the therapeutic potential of Gallium Maltolate, a forgotten metal-based compound with low toxicity and anti-cancer properties. This became the bedrock of our mission to pursue practical, quality-of-life-driven medical innovations.
We aspire to create a new paradigm in medical research, one where success is measured by lives saved. A society where accessible, evidence-based treatments are the norm, not the exception.
Gallium Maltolate (GaM) is an early-stage, well-tolerated compound demonstrating exciting potential to inhibit cancer cell growth and reduce inflammation, particularly in difficult-to-treat brain and liver cancers. We are committed to leading the critical clinical and translational research needed to revive and fully validate this simple yet promising small molecule, focusing specifically on its application in several challenging malignancies and patient groups.
"Once you choose hope, anything's possible."
- Christopher Reeve (Superman)
Glioblastoma (GBM): One of the most aggressive adult brain tumors, GBM often shows poor response to current treatments. GaM's ability to potentially cross the blood-brain barrier and its unique mechanism offer a vital new avenue for therapy.
Hepatocellular Carcinoma (HCC): The most common form of liver cancer. HCC is often resistant to systemic therapy, and GaM's focus on disrupting metabolic pathways common in rapidly dividing cells presents a therapeutic opportunity.
The exceptional safety profile of Gallium Maltolate (Phase 1) gives it significant potential to be a life-changing treatment for the following patient groups:
Pediatric Oncology : For children, who face long-term developmental and neurocognitive damage from aggressive treatments, GaM offers hope for effective therapy with reduced sequelae, crucials for cancers like Medulloblastoma and Diffuse Midline Glioma (DMG).
Geriatric Oncology : Elderly patients often struggle to tolerate standard chemotherapy. GaM's may lower burden on the body, helping to manage cancer while maintaining a balanced quality of life without the debilitating side effects.
Lawrence R. Bernstein received his B.A. and M.A. from Harvard and his Ph.D. from Stanford. Initially, his research was in the physical chemistry and metal geochemistry but later shifted to metal biochemistry and metal-based therapeutics, applying his geochemical knowledge to develop treatments for cancer, infectious diseases, including inflammation and pain. His recent work focuses on the biochemistry and medicinal chemistry of gallium, leading to the development of new therapeutic compounds, Gallium Maltolate which is currently in clinical trials.
Senior Research Scientist at Stanford University, focusing on improving liver cancer diagnosis and treatment using bioinformatics and genomics. Originally from Singapore, she earned her doctorate from the University of Nottingham and completed postdoctoral training in molecular pharmacology at Stanford. She leads various projects in oncology drug development, experimental therapeutics, and drug repositioning.
Medical Bioinformatics Engineer with experience working with researchers and managing clinical trials. Former Director at Deloitte and Commercialisation Senior Business Partner at UNSW, bringing deep expertise in translational research, and innovation strategy.
Scientist & Entrepreneur committed to fostering collaboration and making substantial contributions to the advancement of new medical research. Currently, also involved in the development of a pioneering medical innovation that has been recognized with the prestigious US NASA iTech Award.
Discover how Gallium Maltolate is opening new horizons in cancer treatment, offering hope for patients facing some of the most challenging cancers, learn about its promising medical successes and case studies.
IMPORTANT: Members of the group do not give, or purport to give, any medical advice and the information offered is for general educational purposes only. For further details please read our DISCLAIMER on our Terms and Conditions.
The medical research collaboration is operated by IMMUNOGEX PTY LTD (ABN 88 653 253 448), trading as MedResearch, a Sydney-based research and development company specialising in Life Sciences and Medical Technologies.
Contact
info@medr.com.au
+61 414 456 796
4/27 Rose Cres Regents Park, NSW 2143
Copyright Ⓒ 2025 MedResearch
